Dr Lal PathLabs Ltd. is India’s leading diagnostic laboratory and pathology services provider. It was established in 1949 by Dr S.K. Lal and is headquartered in New Delhi. The company operates a network of over 2000 collection centers and more than 200 laboratories and provides services in over 300 cities and towns across India.
The company offers a wide range of clinical laboratory tests and services, including biochemical tests, immunological tests, microbiology tests, hematology tests, histopathology tests, cytology tests, and molecular diagnostics tests. It also provides a variety of preventive health checkup packages.
Dr Lal PathLabs has a strong presence in the online space and offers services such as online booking and test results, online payment, and home sample collection. The company is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
Recently Dr Lal Path Labs shared its Q3Fy2024 results, and the growth looks impressive. This post will discuss more about Dr LalPathLabs and its share price target for 2024 to 2030 through 2025.
Dr. LalPathLabs Stock History
The stock of Dr Lal PathLabs began trading on the NSE on April 21, 2017, and on the BSE on May 1, 2017. The stock has experienced a steady upward trend since then, with a peak of Rs. 4100 (as of September 9, 2021). Over the past year, the stock has gained approximately 163%.
In November 2023, the company reported a Q2 FY2024 revenue of Rs. 601 crores, up 12.5% YOY.
The company’s strong financial performance and its leadership position in the diagnostic laboratory industry are likely to drive the stock price higher shortly.
Dr Lal PathLabs Q3 FY24 Financial Highlights
- Net Profit: ₹81.3 crore, up by 54% YoY.
- Revenue: Increased by 10% YoY, reaching ₹539 crore from ₹489.4 crore.
- PAT (Profit After Tax): Significantly rose to ₹81.3 crore, compared to ₹52.8 crore in the year-ago period.
- Quarterly Performance: Net profit witnessed a 25% QoQ decline, standing at ₹109.3 crore, and a 10% QoQ decline in revenue from ₹601.3 crore in Q2FY24.
- EBITDA: Improved by 24.6% to ₹141 crore from ₹113 crore.
- EBITDA Margin: 26.1% during the quarter ending December 2023.
- Operational Metrics: Served 6.7 million patients and tested 18.6 million samples, with a sample growth of 7.1% YoY.
- Key Product Programs: Swasthfit contributed to 20% of revenue.
- Digital Initiatives: CHIPs and Recommendation engines continued to enhance patient loyalty and stickiness.
- Strategic Focus: Deepening presence in underserved Tier 3 and 4 markets by opening new labs, supported by a strong hub lab network.
- Market Position: CEO Bharath Uppiliappan highlighted the company’s position among the medical community and patients.
- Share Performance: Dr Lal PathLabs shares were trading 0.19% up on Thursday at ₹2,522.15.
You can buy shares of Dr Lal PathLabs on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). You can buy shares through a stockbroker or an online trading platform.
To buy shares of Dr Lal PathLabs through a stockbroker, you must open a Demat and trading account with the stockbroker. You will have to fill out an account opening form, provide KYC documents, and submit the form with the required fees. Once you have opened the account, you can place an order to buy the shares of Dr Lal PathLabs.
Some online platforms to buy Lal PathLabs Stock are Zerodha, Upstox, 5Paisa, HDFC Securities, Angel Broking, ICICI Direct, Kotak Securities, etc.
| When | Maximum Price | Minimum Price |
| April 2024 | 2,336.40 | 2,031.65 |
| May 2024 | 2,301.87 | 2,001.63 |
| June 2024 | 2,384.74 | 2,073.69 |
| July 2024 | 2,360.89 | 2,052.95 |
| August 2024 | 2,455.33 | 2,135.07 |
| September 2024 | 2,553.54 | 2,220.47 |
| October 2024 | 2,503.47 | 2,176.93 |
| November 2024 | 2,603.61 | 2,264.01 |
| December 2024 | 2,629.65 | 2,286.65 |
As we move into April 2024, it is anticipated that the maximum price of Dr. Lal Pathlabs will reach 2,336.40, signaling a potential bullish trend, while the minimum price is expected to be 2,031.65, indicating support levels for investors. Progressing through the months, by December 2024, the maximum price is projected to surge to 2,629.65, showcasing sustained upward momentum, with the minimum price stabilizing at 2,286.65, suggesting robust support levels for the stock’s valuation. Throughout 2024, Dr. Lal Pathlabs is poised to demonstrate resilience and growth, offering opportunities for investors amidst market fluctuations.
| When | Maximum Price | Minimum Price |
| January 2025 | 2,892.61 | 2,225.09 |
| February 2025 | 2,921.83 | 2,247.56 |
| March 2025 | 2,983.19 | 2,294.76 |
| April 2025 | 2,953.65 | 2,272.04 |
| May 2025 | 2,867.62 | 2,205.86 |
| June 2025 | 2,996.67 | 2,305.13 |
| July 2025 | 2,937.91 | 2,259.93 |
| August 2025 | 3,028.77 | 2,329.82 |
| September 2025 | 3,065.12 | 2,357.78 |
| October 2025 | 3,144.81 | 2,419.08 |
| November 2025 | 3,223.43 | 2,479.56 |
| December 2025 | 3,368.48 | 2,591.14 |
As we step into January 2025, it is anticipated that the maximum price of Dr. Lal Pathlabs will reach 2,892.61, signaling a potential bullish trend, while the minimum price is expected to be 2,225.09, indicating support levels for investors. Progressing through the months, by December 2025, the maximum price is projected to surge to 3,368.48, showcasing sustained upward momentum, with the minimum price stabilizing at 2,591.14, suggesting robust support levels for the stock’s valuation. Throughout 2025, Dr. Lal Pathlabs is poised to demonstrate resilience and growth, offering opportunities for investors amidst market fluctuations.
| When | Maximum Price | Minimum Price |
| January 2026 | 3,469.54 | 2,668.88 |
| February 2026 | 3,558.50 | 2,737.31 |
| March 2026 | 3,697.28 | 2,844.06 |
| April 2026 | 3,624.79 | 2,788.30 |
| May 2026 | 3,519.21 | 2,707.08 |
| June 2026 | 3,677.57 | 2,828.90 |
| July 2026 | 3,605.46 | 2,773.43 |
| August 2026 | 3,716.97 | 2,859.21 |
| September 2026 | 3,847.07 | 2,959.28 |
| October 2026 | 3,947.09 | 3,036.22 |
| November 2026 | 4,045.77 | 3,112.13 |
| December 2026 | 4,146.91 | 3,189.93 |
| When | Maximum Price | Minimum Price |
| January 2027 | 4,229.85 | 3,253.73 |
| February 2027 | 4,338.31 | 3,337.16 |
| March 2027 | 4,507.50 | 3,467.31 |
| April 2027 | 4,419.12 | 3,399.32 |
| May 2027 | 4,290.41 | 3,300.31 |
| June 2027 | 4,483.48 | 3,448.83 |
| July 2027 | 4,395.57 | 3,381.20 |
| August 2027 | 4,531.51 | 3,485.78 |
| September 2027 | 4,690.11 | 3,607.78 |
| October 2027 | 4,812.06 | 3,701.58 |
| November 2027 | 4,932.36 | 3,794.12 |
| December 2027 | 5,055.67 | 3,888.97 |
| When | Maximum Price | Minimum Price |
| January 2028 | 5,156.78 | 3,966.75 |
| February 2028 | 5,289.01 | 4,068.47 |
| March 2028 | 5,495.28 | 4,227.14 |
| April 2028 | 5,387.53 | 4,144.25 |
| May 2028 | 5,230.61 | 4,023.54 |
| June 2028 | 5,465.99 | 4,204.60 |
| July 2028 | 5,358.81 | 4,122.16 |
| August 2028 | 5,524.55 | 4,249.65 |
| September 2028 | 5,717.90 | 4,398.39 |
| October 2028 | 5,866.57 | 4,512.75 |
| November 2028 | 6,013.23 | 4,625.57 |
| December 2028 | 6,163.57 | 4,741.20 |
| When | Maximum Price | Minimum Price |
| January 2029 | 6,286.84 | 4,836.03 |
| February 2029 | 6,448.04 | 4,960.03 |
| March 2029 | 6,699.51 | 5,153.47 |
| April 2029 | 6,568.15 | 5,052.42 |
| May 2029 | 6,376.84 | 4,905.26 |
| June 2029 | 6,663.80 | 5,126.00 |
| July 2029 | 6,533.14 | 5,025.49 |
| August 2029 | 6,735.19 | 5,180.92 |
| September 2029 | 6,970.93 | 5,362.25 |
| October 2029 | 7,152.17 | 5,501.67 |
| November 2029 | 7,330.97 | 5,639.21 |
| December 2029 | 7,514.25 | 5,780.19 |
| When | Maximum Price | Minimum Price |
| January 2030 | 7,664.53 | 5,895.80 |
| February 2030 | 7,861.06 | 6,046.97 |
| March 2030 | 8,167.64 | 6,282.80 |
| April 2030 | 8,007.49 | 6,159.61 |
| May 2030 | 7,774.26 | 5,980.20 |
| June 2030 | 8,124.11 | 6,249.31 |
| July 2030 | 7,964.81 | 6,126.78 |
| August 2030 | 8,211.14 | 6,316.26 |
| September 2030 | 8,498.53 | 6,537.33 |
| October 2030 | 8,719.50 | 6,707.30 |
| November 2030 | 8,937.48 | 6,874.99 |
| December 2030 | 9,160.92 | 7,046.86 |
Lal PathLabs Financial Condition: Last 5 years
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
| Sales + | 1,203 | 1,330 | 1,581 | 2,087 | 2,017 | 2,172 |
| Expenses + | 910 | 987 | 1,145 | 1,526 | 1,527 | 1,592 |
| Operating Profit | 294 | 344 | 436 | 561 | 490 | 580 |
| OPM % | 24% | 26% | 28% | 27% | 24% | 27% |
| Other Income + | 46 | 55 | 51 | 52 | 42 | 65 |
| Interest | 1 | 15 | 16 | 30 | 38 | 32 |
| Depreciation | 38 | 73 | 77 | 108 | 150 | 145 |
| Profit before tax | 301 | 310 | 394 | 475 | 344 | 469 |
| Tax % | 33% | 27% | 25% | 26% | 30% | |
| Net Profit + | 200 | 228 | 296 | 350 | 241 | 333 |
| EPS in Rs | 23.9 | 27.11 | 34.99 | 41.37 | 28.65 | 39.53 |
| Dividend Payout % | 25% | 44% | 57% | 29% | 21% |
Over the period from March 2019 to the trailing twelve months (TTM), the company has displayed commendable financial performance. Sales have steadily increased from ₹1,203 crores in March 2019 to a peak of ₹2,087 crores in March 2022, before slightly decreasing to ₹2,017 crores in March 2023 and rebounding to ₹2,172 crores in the TTM. Operating profit saw consistent growth, rising from ₹294 crores in March 2019 to ₹580 crores in the TTM, with operating profit margins ranging between 24% and 28%. Despite fluctuations, net profit demonstrated an upward trend, reaching ₹350 crores in March 2022, and settling at ₹333 crores in the TTM. Earnings per share (EPS) also showed growth, from ₹23.9 in March 2019 to ₹41.37 in March 2022, before declining to ₹28.65 in March 2023 and rising again to ₹39.53 in the TTM. The dividend payout percentage varied, peaking at 57% in March 2021 and declining to 21% in March 2023, reflecting shifts in the company’s dividend distribution strategy. Overall, these figures illustrate the company’s resilience and ability to navigate changing market conditions while maintaining growth.
FAQs
Will Lal PathLabs Stock price grow in 2024?
The stock price of Dr. Lal PathLabs in 2024 is subject to fluctuations, with projected price targets ranging from 2,001.63 to 2,629.65.
What is the market cap of Dr Lal PathLabs?
As of April 16th, 2024, the market capitalization of Dr Lal PathLabs is 19,453 Cr.
What future is anticipated for Dr Lal PathLabs in 2025?
In 2025, Dr. Lal PathLabs is anticipated to experience fluctuations in its stock price, with the potential for both highs and lows throughout the year, including a maximum price target of 3,368.48 in December.
Can Dr. Lal PathLabs reach 10,000 INR?
It is possible that the stock price of Dr. Lal PathLabs could reach 10,000 INR in the year 2031 or 2032.
However, it is impossible to predict exactly when this may happen as the stock price depends on several factors such as the company’s financial performance, market conditions, and investor sentiment. Investing in Dr Lal PathLabs shares could be a good option to generate returns.
The share price target for Dr. Lal PathLabs in 2030 indicates substantial growth potential, with the maximum price projected to be 9,160.92, suggesting a positive long-term trajectory.
Also Read
Dr Lal PathLabs, a frontrunner in diagnostic services, demonstrates resilience and adaptability in the ever-evolving healthcare sector. The Q3 FY24 results underscore robust growth, aligning with the company’s expansive network and commitment to serving diverse regions. However, the financial journey reveals periodic challenges, as reflected in quarterly fluctuations and a temporary dip in net profit.
Amidst this, the company’s strategic focus on online services and proactive initiatives positions it for sustained success. The share price targets for 2024-2030 indicate a blend of short-term market dynamics and long-term growth potential. Dr Lal PathLabs, with its solid market presence, digital advancements, and historical financial stability, remains a key player in shaping the future of diagnostic healthcare in India.
What did we learn?
Linkedin
